Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Sumatriptan
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Sumatriptan

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A serotonin agonist that acts selectively at 5HT1 receptors.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (976 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of migraine disorders.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; Sumatriptan Succinate; Succinate, Sumatriptan; Imigran; GR-43175; GR43175; GR 43175.

Where it fits in the MeSH classification

Broader topics
Sulfonamides; Tryptamines

Related concepts

  • Migraine Disorders

Research landscape

PubMed indexes 2,386 records tagged with the MeSH heading “Sumatriptan” (counts retrieved 2026-10-31). 170 of them (7.1%) were published from 2020 onward, and the busiest period so far is through 1999 with 948 records.

Reviews account for 439 records (18.4%) and meta-analyses for 42. Randomized controlled trials number 332 (13.9%) as a share of all records on the topic. Randomized trials make up a comparatively large share of this literature, which means many treatment questions have been tested directly.

PubMed records by publication periodthrough 1999: 948 records; 2000-2009: 836 records; 2010-2019: 432 records; 2020 onward: 170 records948through 19998362000-20094322010-20191702020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 1999948
2000-2009836
2010-2019432
2020 onward170
Share of records by publication typeReviews: 18.4 percent; Meta-analyses: 1.8 percent; Randomized controlled trials: 13.9 percentReviews18.4% (439)Meta-analyses1.8% (42)Randomized controlled trials13.9% (332)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 2,386 PubMed records
TypeRecordsShare
Reviews43918.4%
Meta-analyses421.8%
Randomized controlled trials33213.9%

Method: PubMed query "Sumatriptan"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats
Kandasamy R, Lee AT, Morgan MM
2017Research article
Design not recorded in structured metadata
37cc by
PMID 28091820 · DOI · PMC5236037
Migraine headaches in chronic fatigue syndrome (CFS): comparison of two prospective cross-sectional studies
Ravindran MK, Zheng Y, Timbol C, Merck SJ, Baraniuk JN
2011Clinical trial
Design not recorded in structured metadata
37cc by
PMID 21375763 · DOI · PMC3058027
Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery
Cottier KE, Galloway EA, Calabrese EC, Tome ME, Liktor-Busa E, Kim J, et al.
2018Research article
Design not recorded in structured metadata
34cc by
PMID 30073201 · DOI · PMC6071204
Experimental and thermodynamic modeling of sumatriptan solubility in supercritical carbon dioxide for green pharmaceutical applications
Bawazeer S
2025Research article
Design not recorded in structured metadata
1cc by
PMID 41120573 · DOI · PMC12540891

Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats [1]

Research article Kandasamy R, Lee AT, Morgan MM · · 2017 · cited 37 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundThe development of new anti-migraine treatments is limited by the difficulty inassessing migraine pain in laboratory animals.
Closing excerpt
ConclusionsThese data indicate that home cage wheel running is a sensitive, reliable, and clinically relevant method to assess migraine pain in the rat.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (217 words)

BackgroundThe development of new anti-migraine treatments is limited by the difficulty inassessing migraine pain in laboratory animals. Depression of activity is one of the few diagnostic criteria formigraine that can be mimicked in rats. The goal of the present study was to test the hypothesis thatdepression of home cage wheel running is a reliable and clinically relevant method to assess migraine painin rats.MethodsAdult female rats were implanted with a cannula to inject allyl isothiocyanate (AITC) onto the dura to induce migraine pain, as has been shown before. Rats recovered from implantation surgery for 8 days in cages containing a running wheel. Home cage wheel running was recorded 23 h a day. AITC and the migraine medication sumatriptan were administered in the hour prior to onset of the dark phase.ResultsAdministration of AITC caused a concentration-dependent decrease in wheel running that lasted 3 h. The duration and magnitude of AITC-induced depression of wheel running was consistent following three repeated injections spaced 48 h apart. Administration of sumatriptan attenuated AITC-induced depressionof wheel running when a large dose (1 mg/kg) was administered immediately following AITC administration. Wheel running patterns did not change when sumatriptan was given to naïve rats.ConclusionsThese data indicate that home cage wheel running is a sensitive, reliable, and clinically relevant method to assess migraine pain in the rat.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 28091820 · DOI · PMC5236037

Migraine headaches in chronic fatigue syndrome (CFS): comparison of two prospective cross-sectional studies [2]

Clinical trial Ravindran MK, Zheng Y, Timbol C, Merck SJ, Baraniuk JN · · 2011 · cited 37 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundHeadaches are more frequent in Chronic Fatigue Syndrome (CFS) than healthy control (HC) subjects.
Closing excerpt
Clinical trial registrationGeorgetown University IRB # 2006-481
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (331 words)

BackgroundHeadaches are more frequent in Chronic Fatigue Syndrome (CFS) than healthy control (HC) subjects. The 2004 International Headache Society (IHS) criteria were used to define CFS headache phenotypes.MethodsSubjects in Cohort 1 (HC = 368; CFS = 203) completed questionnaires about many diverse symptoms by giving nominal (yes/no) answers. Cohort 2 (HC = 21; CFS = 67) had more focused evaluations. They scored symptom severities on 0 to 4 anchored ordinal scales, and had structured headache evaluations. All subjects had history and physical examinations; assessments for exclusion criteria; questionnaires about CFS related symptoms (0 to 4 scale), Multidimensional Fatigue Inventory (MFI) and Medical Outcome Survey Short Form 36 (MOS SF-36).ResultsDemographics, trends for the number of diffuse "functional" symptoms present, and severity of CFS case designation criteria symptoms were equivalent between CFS subjects in Cohorts 1 and 2. HC had significantly fewer symptoms, lower MFI and higher SF-36 domain scores than CFS in both cohorts. Migraine headaches were found in 84%, and tension-type headaches in 81% of Cohort 2 CFS. This compared to 5% and 45%, respectively, in HC. The CFS group had migraine without aura (60%; MO; CFS+MO), with aura (24%; CFS+MA), tension headaches only (12%), or no headaches (4%). Co-morbid tension and migraine headaches were found in 67% of CFS. CFS+MA had higher severity scores than CFS+MO for the sum of scores for poor memory, dizziness, balance, and numbness ("Neuro-construct", p = 0.002) and perceived heart rhythm disturbances, palpitations and noncardiac chest pain ("Cardio-construct"; p = 0.045, t-tests after Bonferroni corrections). CFS+MO subjects had lower pressure-induced pain thresholds (2.36 kg [1.95-2.78; 95% C.I.] n = 40) and a higher prevalence of fibromyalgia (47%; 1990 criteria) compared to HC (5.23 kg [3.95-6.52] n = 20; and 0%, respectively). Sumatriptan was beneficial for 13 out of 14 newly diagnosed CFS migraine subjects.ConclusionsCFS subjects had higher prevalences of MO and MA than HC, suggesting that mechanisms of migraine pathogenesis such as central sensitization may contribute to CFS pathophysiology.Clinical trial registrationGeorgetown University IRB # 2006-481

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 21375763 · DOI · PMC3058027

Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery [3]

Research article Cottier KE, Galloway EA, Calabrese EC, Tome ME, Liktor-Busa E, Kim J, et al. · · 2018 · cited 34 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Cortical spreading depression (CSD) in the CNS is suggested as a common mechanism contributing to headache.
Closing excerpt
, sumatriptan) to the CNS.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (237 words)

Cortical spreading depression (CSD) in the CNS is suggested as a common mechanism contributing to headache. Despite strong evidence for CNS involvement in headache disorders, drug development for headache disorders remains focused on peripheral targets. Difficulty in delivering drugs across the blood-brain barrier (BBB) may partially account for this disparity. It is known, however, that BBB permeability is increased during several CNS pathologies. In this study, we investigated BBB changes in response to KCl-induced CSD events and subsequent allodynia in rats. Cortical KCl injection in awake, freely moving rats produced facial allodynia with peak intensity between 1.5 and 3 h and CSD induction within 0.5-2 h postinjection. Brain perfusion of 14C-sucrose as a marker of BBB paracellular permeability revealed increased leak in the cortex, but not brainstem, beginning 0.5 h post-KCl injection and resolving within 6 h; no changes in tight junction (TJ) proteins occludin or claudin-5 expression were observed. Acute pretreatment with topiramate to inhibit CSD did not prevent the increased BBB paracellular permeability. CNS delivery of the abortive anti-migraine agent sumatriptan was increased in the cortex 1.5 h post-KCl injection. Surprisingly, sumatriptan uptake was also increased in the brainstem following CSD induction, suggesting regulation of active transport mechanisms at the BBB. Together, these results demonstrate the ability of CSD events to produce transient, time-dependent changes in BBB permeability when allodynia is present and to mediate access of clinically relevant therapeutics (i.e., sumatriptan) to the CNS.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30073201 · DOI · PMC6071204

Experimental and thermodynamic modeling of sumatriptan solubility in supercritical carbon dioxide for green pharmaceutical applications [4]

Research article Bawazeer S · · 2025 · cited 1 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
This study examined the solubility of sumatriptan when dissolved in supercritical carbon dioxide.
Closing excerpt
These findings provide essential experimental data and validated predictive models that are critical for designing eco-friendly supercritical fluid processes, such as the supercritical anti-solvent.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (191 words)

This study examined the solubility of sumatriptan when dissolved in supercritical carbon dioxide. The temperature of the system was varied between 308 and 338 K, and the pressure was ranged between 10 and 30 MPa. The experimental mole fraction and the solubility ranged from 4.30 × 10-6 to 5.26 × 10-5 and from 0.010 to 0.278 g/l respectively with a cross over point of 15 MPa. A total of four semi-empirical models (Chrastil, Bartle et al., K-J, and MST) were evaluated for their potential in facilitating both the correlation and the self-consistency of the data. The K-J method yielded the best outcome, with an AARD of 8.21% and a Radj of 0.991. These models also helped estimate thermal enthalpies ([Formula: see text] = 40.96 kJ mol-1, [Formula: see text] = 59.83 kJ mol-1, and [Formula: see text] = - 18.87 kJ mol-1). Thermodynamic modeling using the PC-SAFT, Peng-Robinson and Soave-Redlich-Kwong combined with mixing rules showed that the PC-SAFT offered better accuracy (AARD = 11.75%, Radj = 0.988). These findings provide essential experimental data and validated predictive models that are critical for designing eco-friendly supercritical fluid processes, such as the supercritical anti-solvent.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41120573 · DOI · PMC12540891

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials [5]
    Cady RK, Sheftell F, Lipton RB, O'Quinn S, Jones M, Putnam DG, et al. · Clin Ther · 2000 · cited 160 times (Europe PMC)
  • Research article Neurogenic inflammation in the context of migraine [6]
    Williamson DJ, Hargreaves RJ · Microsc Res Tech · 2001 · cited 155 times (Europe PMC)
  • Research article Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache [7]
    Plosker GL, McTavish D · Drugs · 1994 · cited 117 times (Europe PMC)
  • Research article The mode of action of sumatriptan is vascular? A debate [8]
    Humphrey PP, Goadsby PJ · Cephalalgia · 1994 · cited 106 times (Europe PMC)
  • Research article Where do triptans act in the treatment of migraine? [9]
    Ahn AH, Basbaum AI · Pain · 2005 · cited 102 times (Europe PMC)
  • Research article Sumatriptan. An updated review of its use in migraine [10]
    Perry CM, Markham A · Drugs · 1998 · cited 99 times (Europe PMC)

References

  1. Kandasamy R, Lee AT, Morgan MM. Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats. . 2017. PMID 28091820 · DOI · PMC5236037
  2. Ravindran MK, Zheng Y, Timbol C, Merck SJ, Baraniuk JN. Migraine headaches in chronic fatigue syndrome (CFS): comparison of two prospective cross-sectional studies. . 2011. PMID 21375763 · DOI · PMC3058027
  3. Cottier KE, Galloway EA, Calabrese EC, Tome ME, Liktor-Busa E, Kim J, et al.. Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery. . 2018. PMID 30073201 · DOI · PMC6071204
  4. Bawazeer S. Experimental and thermodynamic modeling of sumatriptan solubility in supercritical carbon dioxide for green pharmaceutical applications. . 2025. PMID 41120573 · DOI · PMC12540891
  5. Cady RK, Sheftell F, Lipton RB, O'Quinn S, Jones M, Putnam DG, et al.. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther. 2000. PMID 11048903 · DOI
  6. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech. 2001. PMID 11301492 · DOI
  7. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994. PMID 7516861 · DOI
  8. Humphrey PP, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. Cephalalgia. 1994. PMID 7697699 · DOI
  9. Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine?. Pain. 2005. PMID 15836963 · DOI · PMC1850935
  10. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs. 1998. PMID 9617601 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • VemurafenibDrugs and Chemicals
  • TamsulosinDrugs and Chemicals
  • BosentanDrugs and Chemicals
  • CelecoxibDrugs and Chemicals
  • FurosemideDrugs and Chemicals
  • ProbenecidDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

2,386
PubMed records on this heading
7%
published since 2020
439
review articles
332
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • VemurafenibDrugs and Chemicals
  • TamsulosinDrugs and Chemicals
  • BosentanDrugs and Chemicals
  • CelecoxibDrugs and Chemicals
  • FurosemideDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support